LY2140112

LY2140112 is a selective 5-hydroxytryptamine-2c (5-HT2c) receptor agonist developed for the treatment of overweight and obesity. It was investigated in a phase 1, single-center, double-blind, randomized, placebo-controlled dose-escalation study in subjects with overweight or obesity. The drug acts by reducing postprandial triglyceride levels—specifically lowering very low-density lipoprotein (VLDL-V6) triglycerides after a high-fat meal—without significantly affecting total triglycerides or chylomicrons. The mechanism of action involves modulation of lipid metabolism through selective activation of the 5-HT2c receptor[3][4].